2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 2021, 18: 345-362. PMID: 33580222, DOI: 10.1038/s41571-021-00473-5.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsSelection of patientsPD-L1L1 antibodyImmunohistochemistry assaysPD-L1 immunohistochemistry assaysOutcomes of patientsBiomarkers of responseCompanion diagnostic assayTypes of cancerPD-1Clinical outcomesSelection biomarkerProspective comparisonClinical challengeNew therapiesFuture treatmentPatientsSolid tumorsClinical useSpecific agentsInter-assay variabilityBiomarkersCurrent roleDiagnostic assays
2014
Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time
Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM. Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation 2014, 95: 334-341. PMID: 25418580, DOI: 10.1038/labinvest.2014.139.Peer-Reviewed Original ResearchConceptsCold ischemic timeIschemic timeFormalin fixationCompanion diagnostic testingCancer patientsBreast cancerTissue microarrayPhospho-HSP27Breast tumorsDiagnostic testingQuantitative immunofluorescenceAQUA technologyPreanalytical variablesGene expression profilingLoss of antigenicityTissue samplesReproducible assessmentProtein levelsConfidence intervalsSpecimen collectionExpression levelsPhosphorylation levelsAntigenicityRoutine usageResearch settingsA tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue
Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation 2014, 94: 467-474. PMID: 24535259, PMCID: PMC4030875, DOI: 10.1038/labinvest.2014.7.Peer-Reviewed Original ResearchConceptsCold ischemic timeIschemic timeQuantitative immunofluorescenceLevel of expressionTissue qualityER expression levelsBreast cancer casesExpression levelsFormalin fixationInformative epitopesValidation cohortCancer casesBreast cohortProtein statusGlobal assessmentPatient samplesTissue cohortPreanalytical variablesEpitope expressionCohortIntrinsic controlMeasurement of effectsQuality IndexFFPE tissuesEpitopes
2013
Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method
Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method. PLOS ONE 2013, 8: e79901. PMID: 24278211, PMCID: PMC3836903, DOI: 10.1371/journal.pone.0079901.Peer-Reviewed Original ResearchConceptsCore needle biopsyBreast cancer casesResection specimensCancer casesHER2/neu overexpressionPrediction of responsePre-analytic variablesNeu overexpressionTumor resectionNeedle biopsyBreast cancerHER2 immunoreactivityRetrospective collectionHER2Drug trastuzumabClinical implicationsHER2 proteinQuantitative immunofluorescenceResectionPHER2Good responseFurther studiesBiopsyTrastuzumabImmunoreactivity
2011
Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues
Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues. Journal Of Clinical Oncology 2011, 29: 2282-2290. PMID: 21519016, PMCID: PMC3107745, DOI: 10.1200/jco.2010.33.2023.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorClinical Trials as TopicHumansMulticenter Studies as TopicSpecimen HandlingTissue Array AnalysisConceptsMulti-institutional clinical trialsPractice-changing evidenceProportion of patientsCooperative Oncology GroupCooperative group studiesCompanion diagnostic testsCollection of tissuesOncology GroupClinical trialsPathology CommitteeStudy populationCommittee guidelinesSuch trialsDiagnostic testsBiomarker studiesGroup studyPrecious tissuePatientsCancerTissueNumber of assaysTrialsFacility directorsGuidelinesQuantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables
Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation 2011, 91: 1253-1261. PMID: 21519325, PMCID: PMC3145004, DOI: 10.1038/labinvest.2011.75.Peer-Reviewed Original ResearchConceptsCore needle biopsyCold ischemic timePre-analytic variablesNeedle biopsyEstrogen receptorIschemic timeTumor resectionTumor resection specimensAntigenic lossResection specimensTissue biomarkersTotal AktBiopsyPhospho-AktQuantitative immunofluorescencePhospho-ERKPhospho-S6K1Antigenic epitopesTotal ERKResectionTotal proteinCytokeratinImmunological methodsAntigenicitySignificant changes
2006
The value of onsite adequacy assessment of thyroid fine‐needle aspirations is a function of operator experience
Ghofrani M, Beckman D, Rimm DL. The value of onsite adequacy assessment of thyroid fine‐needle aspirations is a function of operator experience. Cancer 2006, 108: 110-113. PMID: 16400635, DOI: 10.1002/cncr.21715.Peer-Reviewed Original ResearchMeSH KeywordsBiopsy, Fine-NeedleFemaleHumansMaleMiddle AgedSpecimen HandlingThyroid DiseasesThyroid GlandThyroid NeoplasmsUltrasonographyConceptsFine-needle aspirationThyroid fine-needle aspirationPalpation-guided fine-needle aspirationNondiagnostic rateOnsite evaluationUS guidancePerformance of FNAImmediate adequacy assessmentCurrent studyLower nondiagnostic rateFinal diagnosisChi-square analysisCytologic diagnosisNondiagnostic specimensNondiagnostic aspiratesPalpationSignificant decreaseDiagnosisImmediate evaluationExperienced radiologistsRadiologistsOperator experienceExperienced operatorsAdequate materialLess experience
2005
Tissue microarrays without cores
Rimm DL. Tissue microarrays without cores. Nature Methods 2005, 2: 492-493. PMID: 15973417, DOI: 10.1038/nmeth0705-492.Peer-Reviewed Original Research